drugset / Trial / NCT01879020

Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 After Multiple Doses in Healthy Subjects

NCT01879020

Phase 1 Completed 61 enrolled Tanabe Pharma Corporation
RandomizedSingle-groupDouble-blindTreatment

Summary

The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of TA-8995 after multiple doses in healthy adult male subjects

Timeline

Start
2009-08
Primary completion
2010-06
Completion
2010-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Obicetrapib Small molecule 1 mg
Subject Obicetrapib Small molecule 2.5 mg
Subject Obicetrapib Small molecule 5 mg
Subject Obicetrapib Small molecule 10 mg
Subject Obicetrapib Small molecule 25 mg

Indications